Modest improvement of metabolic and behavioral deficits with long-term ambroxol treatment in a Pink1(-/-)SNCA(A53T) double mutant mouse model of Parkinson's disease
Acta Pharmacol Sin. 2025 Dec 8. doi: 10.1038/s41401-025-01690-9. Online ahead of print.ABSTRACTParkinson's disease (PD) involves α-synuclein (αSyn) oligomerization and aggregation, processes facilitated by glycosphingolipids. Defective glycosphingolipid transport and degradation-especially via the l

